Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation

Soeki, Takeshi; Matsuura, Tomomi; Bando, Shigenobu; Tobiume, Takeshi; Uematsu, Etsuko; Ise, Takayuki; Kusunose, Kenya; Yamaguchi, Koji; Yagi, Shusuke; Fukuda, Daiju; Yamada, Hirotsugu; Wakatsuki, Tetsuzo; Shimabukuro, Michio; Sata, Masataka

doi:10.1016/j.jjcc.2015.12.007

Cited by 37 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Compared with CAD and HF there is much less data from clinical trials reported on circulating miRNAs in diagnostic approaches for AF. Some clinical trials, however, identified circulating miRNAs including miR-499 [44], miR-328 [43,45], miR-150 [46], miR-409-3p, and miR-432 [41], miR-126 [126]. None of the reported miRNAs were validated and all trials refer to rather small patients cohorts.…”

Section: Atrial Fibrillation (Af)mentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Atrial Fibrillation (Af)mentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

show abstract

“…In addition, plasma miR-1 levels were also higher in the LAA than in the PV in AF patients. Authors did not inform conditions of sample processing, but they stated that total RNA was extracted using TRIzol LS RNA Isolation Kit (Invitrogen) [1]. …”

Section: Plasma Mirna Involved In Afmentioning

confidence: 99%

“…It is the most common type of arrhythmia in clinical practice, and it is a significant health, social, and economic problem, increasing the risk of stroke, heart failure, and morbidity and disability, especially in the elderly [1]. According to the American Heart Association, AF can be classified as first detected episode of AF, paroxysmal when AF is sustained for less than 7 days and terminates spontaneously (PAF), persistent when AF is sustained beyond 7 days (PersAF, can be long-standing when AF persists for more than 1 year), and permanent when cardioversion attempts have failed or have not been tried [2].…”

Section: Introductionmentioning

confidence: 99%

Circulating MicroRNAs as Potential Biomarkers of Atrial Fibrillation

Silva

Araújo

Freitas

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common supraventricular arrhythmia in the population. MicroRNAs (small endogenous noncoding RNAs) are attractive candidates as biomarkers for AF, especially considering that miRNAs are stable and are detected within easily accessible biofluids such as blood. In this review, we selected twelve studies (2012 to 2016) that were classified according to the sample type. We aimed to provide an overview of the role of circulating miRNAs in AF and to discuss the variability of the results, seeking to improve the perspective of the use of miRNAs as potential noninvasive biomarkers for this heart disease.

show abstract

“…However, although studies have already shown that some miRNAs have different expression profiles between biofluids and tissues, Soeki et al. observed similar expression profiles between atrial tissue and plasma of AF patients, strengthening the idea that miRNAs could be disease specific …”

Section: Discussionmentioning

confidence: 99%

“…It is possible that patients with different types of AF will exhibit different miRNA expression pro- observed similar expression profiles between atrial tissue and plasma of AF patients, strengthening the idea that miRNAs could be disease specific. 10 An important factor is the difference in the expression of the same miRNA between different types of human samples. A study performed by our research group observed that the variability of miRNA could be related to the different types of samples (e.g., plasma, serum, platelet, and whole blood) and the methods of analysis used in studies.…”

Section: Discussionmentioning

confidence: 99%